Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: GenomeWeb s Weekly Personnel Roundup in the Genomics Sector: Oct 31, 2001

NEW YORK, Oct. 31 — AnVil Informatics  has appointed Richard Gill as president and CEO, the company said on Wednesday. 

Gill replaces former CEO Howard Berke, who will remain as a member of the board of directors. Former president Michael McManus is now executive vice president and chief operating officer. 

Gill was previously president and CEO of ActiveCyte, a Newton, Mass.-based firm specializing in marketing and licensing intellectual property in the life sciences industry. 

AnVil is based in Lowell, Mass.

________________________________________________________________

US Genomics  has hired Michael B. Olex as senior vice president for operations and manufacturing, the company said.  

Olex will be responsible for commercializing the company’s direct linear DNA analysis technology and “take it from the research stage and beyond,” a US Genomics spokesman said. 

US Genomics, based in Woburn, Mass., develops technologies for linear analysis of DNA for the drug discovery, pharmacogenomics, and diagnostics industries. 

________________________________________________________________

PamGene International  appointed J.A.M. (Hans) van Beek as vice president of business development and Nadia Danhash as business manager, the company said on Oct. 26.  

Van Beek will be responsible for closing new partnerships with other pharmaceutical and biotech companies. Danhash will develop the firm’s relationship with Japan’s Olympus Optical.

Van Beek, 40, was previously business manager of Crystallics, a Dutch company specializing in structure determination in drug design. Danhash, 38, was most recently with Amersham in the UK and the US. 

Both individuals started their new jobs on Oct. 1. PamGene is located in `s-Hertogenbosch, the Netherlands.

________________________________________________________________

Biomira  announced the resignation of Chief Operating Officer Mark Young , the company said on Oct. 26. The move is effective Dec. 31.

Young will continue to consult with the Edmonton, Canada-based company, which focuses on immunotherapeutics and cancer vaccine research, until June 30, 2002. The firm will not seek his replacement until then. 

________________________________________________________________

Motorola Life Sciences  has appointed Gary Thomas , a veteran of Beckman Coulter, to a new role as customer support director. In Thomas’ most recent position, he oversaw all customer service and administrative operations in the central United States and Canada. 

________________________________________________________________

Genaissance Pharmaceuticals  has promoted J. Claiborne Stephens to vice president of genetics, the company said on Oct. 22. 

In this new role, Stephens, formerly executive director of population genomics, will direct the Genaissance division that develops pharmacogenomic products. 

Stephens, 47, joined the company in April 1999. He was previously head of bioinformatics at the National Cancer Institute’s Laboratory of Genomic Diversity, and is known for his pioneering work in population genetics and haplotype discovery techniques.

_________________________________________________________________

Geneticist Ranajit Chakraborty  has been appointed as director of the new University of Cincinnati Center for Genome Information , the University of Cincinnati Medical Center announced on Oct. 18. 

The new center will focus on genetic research into complex diseases like cancer, diabetes, and Alzheimer’s and Parkinson’s diseases. 

Chakraborty will also be the first Robert A. Kehoe Chair of Environmental Health. The position has a total endowment of $2 million.

Chakraborty, an expert on DNA forensics, was a genetics professor at the University of Texas Health Science Center in Houston. He is also a founding fellow of the American College of Epidemiology. Chakraborty has also worked with the New York Medical Examiner’s Office and the FBI to identify remains from the Sept.11 terrorist attacks on the World Trade Center.

________________________________________________________________

Mark Boguski  was elected to the Institute of Medicine of the National Academy of Sciences  on Oct. 15.  

Boguski, formerly senior vice president of genomics at Rosetta Inpharmatics, is now a consultant with the company.

Boguski joined Rosetta in June 2000 as senior vice president of research and development. He was one of the founding members of the National Center for Biotechnology Information, and is known for his work in bioinformatics and genomics research. 

________________________________________________________________

Promoted? Changing jobs? GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected] .

PEOPLE, a roundup of personnel comings and goings in the genomics sector, appears every Wednesday.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.